NMS1286937 (NMS-P937)

Background Information:

NMS1286937 (NMS-P937) is an orally bioavailable, small-molecule
Polo-like kinase 1 (PLK1) inhibitor with potential antineoplastic
activity. NMS-1286937 selectively and effectively inhibits PLK1 (with
IC50 at low nM), inducing selective G2/M cell-cycle arrest followed by
apoptosis in a variety of tumor cells while causing reversible
cell-cycle arrest at the G1 and G2 stages without apoptosis in normal
cells. It is currently in clinical trials.

Reference:

1. A. Casolaro, et al., The Polo-Like Kinase 1 (PLK1) inhibitor
NMS-P937 is effective in a new model of disseminated primary CD56+ acute
monoblastic leukaemia. PLoS One, 2013; 8(3):e58424.
2. B. Valsasina, et al., NMS-P937, an orally available, specific
small-molecule polo-like kinase 1 inhibitor with antitumor activity in
solid and hematologic malignancies. Mol Cancer Ther. 2012 Apr; 11(4):
1006-16.* The product has passed the most rigorous analysis for an
organic compound, exclusively from CHEMIETEK.

APIM050206: NMS1286937 (NMS-P937)

CAS No.: 1034616-18-6.
Molecular Formula: C₂₄H₂₇F₃N₈O_3.
Molecular Weight: 532.5.
Purity: >99.5% Purity (HPLC, detected at 214 and 254 nm).
QC: HPLC-MS, ¹HNMR and Quantitative Elemental Analysis.
Solubility: Soluble in DMSO, and water with 1 eq. of HCl.
Storage: Store at 0°C (short term), -20°C (long term), desiccated.